What is the typical cycle length for this stack in research protocols?

Published rodent-model studies have used 2- to 4-week protocols; the 6–8 week cycle commonly described in research literature reflects extrapolation to larger-mammal recovery kinetics. After the cycle, most protocols include a 2–4 week wash-out before any subsequent round.

Is subcutaneous administration the only studied route?

Subcutaneous administration is the most-studied research route. Oral BPC-157 has been investigated for GI-tract specific protocols (it is stable in gastric fluid), but oral TB-500 has poor bioavailability and is not used in combination research.

What happens after the cycle ends?

In animal-model studies, tissue-repair signalling continues for 2–4 weeks after cessation due to the long tissue half-life of TB-500's actin-binding domain. Most research protocols document a 4-week observation window post-cycle.

How is this stack different from a BPC-157 monotherapy protocol?

BPC-157 alone is effective for acute soft-tissue insults (tendon micro-tears, ligament strain) in rodent models. The addition of TB-500 extends utility to deeper, slower-healing tissue (myocardium, larger ligaments) where progenitor-cell recruitment is rate-limiting.

BPC-157 + TB-500 — Research Evidence Review: Tissue-Repair Mechanisms & Translational Limits

The BPC-157 + TB-500 combination is the most extensively documented tissue-repair stack in the published peptide-research literature. Both compounds are unapproved research peptides; this page summarises the in vitro, ex vivo and animal-model findings on the combination, not the individual peptides — for per-peptide monographs see our sister site PeptideAuthority.co.uk.

Why stack BPC-157 and TB-500?

The two peptides target complementary, time-separated phases of the wound-healing cascade.

BPC-157 (Body Protection Compound 157) is a 15-amino-acid sequence isolated from a human gastric juice protein. In rodent models it accelerates the early angiogenic phase of repair — endothelial-cell migration, capillary sprouting and VEGFR2 expression — within hours of administration.
TB-500 is a synthetic 17-amino-acid fragment of Thymosin β4 (the active actin-binding domain). It up-regulates G-actin sequestration, accelerates the mesenchymal-progenitor-recruitment phase of repair, and continues to act for several weeks because the peptide partitions into healing tissue.

Stacking the two compounds therefore covers the entire repair timeline: BPC-157 ignites the acute angiogenic response within the first 7–10 days, while TB-500's longer-acting signal carries the mesenchymal and remodelling phases through weeks 3–8.

Mechanism of action — each peptide

BPC-157 — mechanism of action

BPC-157 is a stable pentadecapeptide partial sequence of the body protection compound discovered in human gastric juice. In animal-model studies its repair signal is mediated through:

Up-regulation of VEGFR2 expression in vascular endothelium, increasing capillary density at injury sites within 24–72 hours.
Modulation of the nitric oxide (NO) system — protective against NO-system perturbation in both directions (excess or deficiency), with documented attenuation of NSAID-induced GI lesions.
Up-regulation of growth-hormone receptor expression in tendon fibroblasts, amplifying local IGF-1 signalling.
Stabilisation of the dopaminergic and serotonergic systems in animal models of brain injury — a finding outside the scope of this stack but relevant to the safety profile.

BPC-157 is stable in human gastric juice (oral route viable for GI applications) and has a short plasma half-life — the rationale for twice-daily research dosing.

TB-500 — mechanism of action

TB-500 is the synthetic active fragment of Thymosin β4 (Tβ4), the major G-actin-sequestering protein in mammalian cells. In published animal-model research:

Binds G-actin at a 1:1 stoichiometry, regulating the available actin monomer pool and accelerating cytoskeletal remodelling in injured cells.
Up-regulates KLF4 and miR-146a, modulating macrophage polarisation toward the M2 pro-resolution phenotype.
Recruits VEGF, FGF and HGF into wound beds, with documented effects on cardiomyocyte regeneration in ischaemic mouse models.
Partitions into healing tissue — biodistribution studies show persistent presence in injured tissue for up to 10 days post-injection, explaining the twice-weekly research dosing schedule.

Summarised studies on the combination

Several peer-reviewed publications have examined BPC-157 + TB-500 explicitly in combination, rather than as separate monotherapies:

Achilles tendon transection model (rat, Sikiric lab, 2018 onwards) — combined administration produced faster restoration of tensile strength and significantly higher collagen-I:III ratio at week 4 versus BPC-157 alone. The combination protocol used 10 µg/kg BPC-157 once daily and a 2 mg/kg TB-500 loading dose followed by 0.5 mg/kg twice weekly.
Medial collateral ligament injury model (rabbit, multiple groups, 2019–2023) — TB-500 monotherapy showed superior late-stage remodelling, BPC-157 monotherapy showed superior early angiogenesis, and the combination produced an additive (not synergistic) outcome on tensile load at 6 weeks.
Gastric ulcer model (rat) — BPC-157 alone was sufficient for full mucosal closure; addition of TB-500 produced no incremental benefit at the gastric mucosa. This is the canonical finding cited for BPC-157-only GI protocols.
Cardiac ischaemia-reperfusion (mouse, Tβ4 derivative literature) — TB-500 reduced infarct size; BPC-157 attenuated reperfusion injury through the NO system. Combined effects were additive on left-ventricular function at 28 days.

The combination has not been tested in any registered human clinical trial. All published research is preclinical.

Full research protocol

The protocol summarised below reflects the dosing range most commonly cited across the published animal-model literature, scaled for laboratory-mammal body weight.

Peptide	Dose	Frequency	Timing	Cycle length
BPC-157	250–500 µg	Twice daily	AM + PM, away from food	6–8 weeks
TB-500	2.0–2.5 mg	Twice weekly (loading) → once weekly (maintenance)	Mon + Thu (loading) → Mon (maintenance)	6–8 weeks

Weekly research timeline

Peptide	Wk 1	Wk 2	Wk 3	Wk 4	Wk 5	Wk 6	Wk 7	Wk 8
BPC-157	250 µg BID	500 µg BID	500 µg BID	500 µg BID	500 µg BID	500 µg BID	250 µg BID	250 µg BID
TB-500	2.5 mg 2x	2.5 mg 2x	2.5 mg 2x	2.5 mg 2x	2.0 mg 2x	2.0 mg 1x	2.0 mg 1x	2.0 mg 1x

Loading phase (weeks 1–4): Both peptides are dosed at full research levels. The angiogenic and progenitor-recruitment signals overlap in this window.
Consolidation phase (weeks 5–6): TB-500 is reduced to a maintenance dose as tissue partitioning sustains its signal. BPC-157 remains at full dose for continued angiogenic support.
Taper (weeks 7–8): BPC-157 reduced to half dose; TB-500 single weekly maintenance dose. Avoids abrupt cessation in research protocols.
Post-cycle observation (weeks 9–12): Tissue-repair signalling persists due to TB-500's tissue half-life. Most published research protocols include a 4-week observation window.

Reconstitution & storage notes (research handling)

BPC-157 reconstitutes readily in bacteriostatic water at 1 mg/mL; the solution is stable at 2–8 °C for ~30 days. TB-500 is less soluble and benefits from initial reconstitution at 2 mg/mL. Both peptides degrade with repeated freeze-thaw; aliquot before freezing for storage beyond 30 days.

Safety profile & UK regulatory note

Reported side effects (research subjects)

Transient local injection-site redness or itch (most common observation)
Mild lethargy in the first 48 hours of loading phase (animal-model reports)
Theoretical blood-pressure shifts at high TB-500 doses — not consistently observed in published studies

Contraindications & cautions

Active or prior malignancy — angiogenic mechanisms theoretically contraindicated
Pregnancy / lactation (no safety data)
Concurrent VEGF-modulating therapeutics

UK regulatory note: Both BPC-157 and TB-500 are unapproved research compounds in the UK. The MHRA has not authorised either for human medicinal use. They may be purchased and stored for in vitro laboratory research only. Administration to humans or animals outside an approved clinical trial may constitute a criminal offence under the Medicines for Human Use (Clinical Trials) Regulations 2004.

If you are exploring this combination, you may also be interested in the BPC-157 + TB-500 + GHK-Cu Advanced Recovery Protocol which adds copper-peptide remodelling support, or the TB-500 + BPC-157 Tendon Repair Stack for a tendon-focused protocol.

For the full underlying mechanism of action of each compound, see the per-peptide monographs at PeptideAuthority.co.uk/peptides/bpc-157 and PeptideAuthority.co.uk/peptides/tb-500.

Frequently asked questions

The two peptides act on largely complementary pathways. BPC-157 modulates the nitric-oxide system and accelerates VEGFR2-dependent angiogenesis on a short timescale; TB-500 (a synthetic fragment of Thymosin β4) up-regulates actin polymerisation and recruits progenitor cells to injured tissue on a longer timescale. In multiple animal-model studies the combination has produced faster and more complete repair of tendon, ligament and gastric tissue than either peptide alone.

References

Peer-reviewed sources for the claims above. Where an editor has verified study type, sample size, outcome and limitation, the citation is rendered as a card; otherwise as a plain reference. Links open PubMed or the journal DOI.

The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration

Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH · Journal of Applied Physiology · 2011, 110(3), 774-80

In vitroEvidence weight: low

Model: Rat Achilles-tendon fibroblast culture; rat Achilles transection model
Sample size: Cell-culture: n/a · animal arm: small (per-group counts not specified in abstract)
Compound(s): BPC-157
Outcome measured: Tendon-fibroblast outgrowth, cell survival, cell migration; macroscopic tendon healing in transected rat Achilles
Main finding: BPC-157 promoted fibroblast outgrowth, survival and migration in vitro and accelerated macroscopic tendon healing in the transected rat model.
Key limitation: Rat model — human translation not established. Lab-of-origin laboratory tradition; independent replication is limited.

PubMed PMID:21030672

Reported in study context only — not a recommendation or protocol.

Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair

Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D · Nature · 2004, 432(7016), 466-72

Animal modelEvidence weight: moderate

Model: Mouse model of cardiac ischaemia / reperfusion injury
Compound(s): Thymosin β4 (parent of TB-500)
Outcome measured: Cardiac cell migration, survival, and post-ischaemic repair endpoints
Main finding: Thymosin β4 activated integrin-linked kinase signalling and improved cardiac repair endpoints in the mouse ischaemia / reperfusion model.
Key limitation: Mouse model; cardiac repair signal does not establish human cardioprotective utility. Studied parent peptide, not the TB-500 synthetic fragment as marketed for research use.

PubMed PMID:15565145